Company profilePharmaceutical#330 of 1,318 in Pakistan✓ No DRAP alerts

Lahore Chemical and Pharmaceutical Works Pvt. Ltd.

Pharmaceutical company · 53 brands · 46 molecules

Ranked #6 of 20 companies in Cancer

53 registered products 24 pharmaceutical brands 46 distinct molecules 0 DRAP alerts

Company overview

53
registered products
24
pharmaceutical brands
46
distinct molecules
5
therapeutic classes
0
DRAP alerts

Lahore Chemical and Pharmaceutical Works Pvt. Ltd. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 53 product registrations across 46 distinct molecules. Its portfolio is concentrated in Cancer and Antineoplastics. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Lahore

6 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Other Beta-Lactam, Cephalosporins & Penems 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

5
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20255

Top molecules by brand count

Artemether3 brands
Levofloxacin3 brands
Azithromycin2 brands
Methotrexate2 brands
Moxifloxacin2 brands
Ketamine2 brands
Bupivacaine2 brands
Protamin1 brand
Metformin1 brand

Therapeutic classes

Cancer · 1Antineoplastics · 1Pain Management · 1Anaesthetic, Local · 1Quinolone Antibacterials · 1

Conditions treated

Oncology · 1Anaesthesia · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official60 products · Rs 15.12 – Rs 3,417.64
DVAGO2 products · Rs 542.5 – Rs 2,726
Servaid3 products · Rs 269.2 – Rs 764
Median across source: Rs 324.71

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

NEUTRO PHARMA (PVT) LTD.15 shared molecules
IRZA PHARMA (PVT) LTD.11 shared molecules
Pharmasol (Pvt) Ltd.9 shared molecules
EPHARM LABORATORIES9 shared molecules
Sante (Private) Limited9 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

NEUTRO PHARMA (PVT) LTD. holds 125 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAmikacinAnastrazoleAnastrozole
IRZA PHARMA (PVT) LTD. holds 115 molecules not in this portfolio
AcetazolamideAcyclovirAdrenalineAlbendazoleAlbuterolAmikacin
BOSCH PHARMACEUTICALS (PVT) LTD. holds 153 molecules not in this portfolio
AmikacinAmlodipineAmoxicillinAmoxicillin SodiumAmoxicillin …50Mg Clavulanic Acid 12.5 MgAmoxycillin

Get the full profile for Lahore

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.